Some studies have looked at the prognostic significance of TP53 alteration in ovarian cancers, and addressed the possibility that the clinical behaviour of tumours with TP53 alterations might be significantly different from that of tumours without TP53 alterations (Kohler et al, 1993; Kupryjanczyk et al, 1995; Geisler et al, 1997; Shahin et al, 2000; Fallows et al, 2001; Suzuki et al, 2001; Valverde et al, 2001). Here, TP53 is linked to neoplasm.